Meng Wang1, Derick R Peterson2, Spencer Rosero3, Scott McNitt4, David Q Rich5, Christopher L Seplaki6, Bronislava Polonsky4, Ilan Goldenberg4, Wojciech Zareba7. 1. Clinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA; Division of Epidemiology, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA. 2. Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA. 3. Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA. 4. Clinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA. 5. Division of Epidemiology, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA; Division of Pulmonary and Critical Care, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, New York, USA. 6. Division of Epidemiology, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA; Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA. 7. Clinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: wojciech_zareba@urmc.rochester.edu.
Abstract
BACKGROUND: The effectiveness of implantable cardioverter-defibrillators (ICDs) on reducing mortality has not been well studied in patients with long QT syndrome (LQTS). OBJECTIVES: This study aimed to assess the survival benefits of ICDs in the overall LQTS population and in subgroups defined by ICD indications. METHODS: This study included 3,035 patients (597 with ICD) from the Rochester LQTS Registry with a QTc ≥470 milliseconds or confirmed LQTS mutation. Using multivariable Cox proportional hazards models, the risk of all-cause mortality, all-cause mortality before age 50 years, and sudden cardiac death (SCD) were estimated as functions of time-dependent ICD therapy. Indication subgroups examined included patients with: 1) nonfatal cardiac arrest; 2) syncope while on beta-blockers; and 3) a QTc ≥500 milliseconds and syncope while off beta-blockers. RESULTS: During the 118,837 person-years of follow-up, 389 patients died (137 before age 50 years, and 116 experienced SCD). In the entire population, patients with ICDs had a lower risk of death (HR: 0.54; 95% CI: 0.34-0.86), death before age 50 years (HR: 0.29; 95% CI: 0.14-0.61), and SCD (HR: 0.22; 95% CI: 0.09-0.55) than patients without ICDs did. Patients with ICDs also had a lower risk of mortality among the 3 indication subgroups (HR: 0.14; 95% CI: 0.06-0.34; HR: 0.27; 95% CI: 0.10-0.72; and HR: 0.42; 95% CI: 0.19-0.96, respectively). CONCLUSIONS: ICD therapy was associated with a lower risk of all-cause mortality, all-cause mortality before age 50 years, and SCD in the LQTS population, as wells as with a lower risk of all-cause mortality in indication subgroups. This study provides evidence supporting ICD implantation in patients with high-risk LQTS.
BACKGROUND: The effectiveness of implantable cardioverter-defibrillators (ICDs) on reducing mortality has not been well studied in patients with long QT syndrome (LQTS). OBJECTIVES: This study aimed to assess the survival benefits of ICDs in the overall LQTS population and in subgroups defined by ICD indications. METHODS: This study included 3,035 patients (597 with ICD) from the Rochester LQTS Registry with a QTc ≥470 milliseconds or confirmed LQTS mutation. Using multivariable Cox proportional hazards models, the risk of all-cause mortality, all-cause mortality before age 50 years, and sudden cardiac death (SCD) were estimated as functions of time-dependent ICD therapy. Indication subgroups examined included patients with: 1) nonfatal cardiac arrest; 2) syncope while on beta-blockers; and 3) a QTc ≥500 milliseconds and syncope while off beta-blockers. RESULTS: During the 118,837 person-years of follow-up, 389 patients died (137 before age 50 years, and 116 experienced SCD). In the entire population, patients with ICDs had a lower risk of death (HR: 0.54; 95% CI: 0.34-0.86), death before age 50 years (HR: 0.29; 95% CI: 0.14-0.61), and SCD (HR: 0.22; 95% CI: 0.09-0.55) than patients without ICDs did. Patients with ICDs also had a lower risk of mortality among the 3 indication subgroups (HR: 0.14; 95% CI: 0.06-0.34; HR: 0.27; 95% CI: 0.10-0.72; and HR: 0.42; 95% CI: 0.19-0.96, respectively). CONCLUSIONS: ICD therapy was associated with a lower risk of all-cause mortality, all-cause mortality before age 50 years, and SCD in the LQTS population, as wells as with a lower risk of all-cause mortality in indication subgroups. This study provides evidence supporting ICD implantation in patients with high-risk LQTS.
Authors: Christian Jons; Arthur J Moss; Ilan Goldenberg; Judy Liu; Scott McNitt; Wojciech Zareba; Ming Qi; Jennifer L Robinson Journal: J Am Coll Cardiol Date: 2010-02-23 Impact factor: 24.094
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: Justin M Horner; Masayoshi Kinoshita; Tracy L Webster; Carla M Haglund; Paul A Friedman; Michael J Ackerman Journal: Heart Rhythm Date: 2010-09-17 Impact factor: 6.343
Authors: A J Moss; W Zareba; W J Hall; P J Schwartz; R S Crampton; J Benhorin; G M Vincent; E H Locati; S G Priori; C Napolitano; A Medina; L Zhang; J L Robinson; K Timothy; J A Towbin; M L Andrews Journal: Circulation Date: 2000-02-15 Impact factor: 29.690
Authors: James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss Journal: J Am Coll Cardiol Date: 2008-04-08 Impact factor: 24.094
Authors: Carla Spazzolini; Jamie Mullally; Arthur J Moss; Peter J Schwartz; Scott McNitt; Gregory Ouellet; Thomas Fugate; Ilan Goldenberg; Christian Jons; Wojciech Zareba; Jennifer L Robinson; Michael J Ackerman; Jesaia Benhorin; Lia Crotti; Elizabeth S Kaufman; Emanuela H Locati; Ming Qi; Carlo Napolitano; Silvia G Priori; Jeffrey A Towbin; G Michael Vincent Journal: J Am Coll Cardiol Date: 2009-08-25 Impact factor: 24.094
Authors: Arthur J Moss; Claudio Schuger; Christopher A Beck; Mary W Brown; David S Cannom; James P Daubert; N A Mark Estes; Henry Greenberg; W Jackson Hall; David T Huang; Josef Kautzner; Helmut Klein; Scott McNitt; Brian Olshansky; Morio Shoda; David Wilber; Wojciech Zareba Journal: N Engl J Med Date: 2012-11-06 Impact factor: 91.245